RxDoctor Payments Data

Bishan Chakravarty, MD

Nephrology · Farmington, MONPI 1790030195

Payments from drug & device makers

$3,542in general payments, 2019–2025

Across 196 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vantive US Healthcare LLC$1K
  • Vifor Pharma, Inc.$484
  • Otsuka America Pharmaceutical, Inc.$428
  • Travere Therapeutics, Inc.$422
  • OPKO Pharmaceuticals, LLC$321
  • Akebia Therapeutics Inc$116
  • plus $408 from 7 others

What the payments were for

  • Travel & lodging$1,07130%
  • Food & beverage$2,07058%
  • Education$40211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,542 in reported general payments places this provider in the 70th percentile of 253 nephrology providers in Missouri.

See all nephrology providers in Missouri

Medicare billing

Part B allowed, 2024
$108,924
Medicare patients
416
Services billed
1,492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol32$32,890
Sevelamer Carbonate30$2,407
Calcitriol176$2,377
Potassium Chloride79$1,790
Bumetanide28$1,035
Furosemide239$960
Amlodipine Besylate178$742
Losartan Potassium106$719
Labetalol Hcl15$553
Nifedipine ErNifedipine14$552
Carvedilol84$537
Hydralazine Hcl42$462
Spironolactone32$312
Lisinopril65$290
Metoprolol Succinate14$247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$30$32,89032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 253 nephrology providers in Missouri.

Other nephrology in Farmington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →